Want to submit or suggest content for the MiMedia Clinical Library?
Contact us here
EPG Online is not responsible for external content
Working with our pharmaceutical industry partners we have compiled the EPG educational library. The library contains interactive educational resources from specific drug treatments through to more general disease and management guides. The content is classified by therapeutic area and can be accessed by clicking the links below.
In order to access the following content you must be a qualified physician or other medical professional, by clicking any of the links within the educational library you are both confirming your status as a healthcare professional and agreeing to our terms of use.
What’s in this Alzheimers Knowledge Centre?
Prevalence of Alzheimers | Symptoms of Alzheimers | The stages Of Alzheimers | Types of Dementia | Disease Progression | Treatment Options | Cholinesterae Inhibitors | NMDA Receptors Antagonists | Pipeline Treatments | Downloads | Clinical Studies | Useful Links | Patient Resources | Tips for Caregivers | Downloads for Patients | What the Experts Say | Active Ingredient & MoA | Indication & Diagnosis | Dosage Application | Evaluating Success | Side Effects & Interactions | Prescription & Costs | Acetylcholine | Agnosia | Apagia | Amyloid precursor protein | Antagonist | Aphasia | Apoptosis | Apraxia | Atrophy | ß-amyloid | Behavioural symptoms | Cognitive functions | Cognitive symptoms | Cyclooxygenase | Dysphasia | Dyspraxia | Encephalopathy | Excitotoxicity | γ-secretase | Glutamate | Hippocampus | Ischemic | Limbic system | Long-term potentiation | Litochondrium | MK-801 | Myoclonus | N-methyl-D-aspartate | NSAID | Neurodegeneration | Nucleus basalis magnocellularis | Parietal lobe | PCP | Plaque | Quinolinic acid | Synaptic cleft | Tangles | Temporal lobe
Learn more about Arthritis...
What’s in this Arthritis Knowledge Centre?
Osteoarthritis (OA) | Rheumatoid Arthritis | Inflammatory Arthritis | Diagnosis | Pain Assessment | Pain Management | Children and Older Adults | Treatment options | Non-Pharmacological Treatment | Pharmacological | Complementry Therapy | Surgery | Resources: Physicians | Resources: Patients
What’s in this Asthma Knowledge Centre?
Home | Definition | Prevalence | Burden | Causes of Asthma | Development & Progression of Asthma | Pathophysiology | The asthmatic response | Asthmatic Inflammation | Inflammation in the peripheral airways | Diagnosing | Assessment | Spirometry | Airway Responsiveness | Signs and Symptoms | Levels of asthma control | Classification | Education | Risk Factors | Non-Pharmacological | Pharmacological - Treatment steps for achieving control | stepwise approach | Corticosteroids | Alvesco | Pharmacokinetics | Pharmacodynamics | Clinical efficacy | Safety | Summary of Product Characteristics (SPC) | Monitoring | Resources
What’s in this Benign prostatic hyperplasia Knowledge Centre?
Understanding BPH: Definition | The Prostate |BPH Definition | BPH Clinical Features | Progression of BPH | Clinical Features | Prevalence and Burden | Management of BPH: Watchful Waiting | Phytotherapy | Pharmacotherapy | Surgical Interventions | Other Minimally Invasive Treatments: including Thermotherapy | Dutasteride: Product Characteristics | Efficacy Data | Safety and Tolerability Data | Effect on PSA | Additional Resources: BPH Guidelines| References | 5a-reductase | a-blocker | acute urinary retention (AUR) | anabolic steroid | androgen | anti-androgen | anticholinergic drugs | apoptosis benign prostatic hyperplasia (BPH) | cholestyramine | clastogen | cytochrome P450 | diazepam | digital rectal examination (DRE) | digoxin |dihydrotestosterone (DHT) | diltiazem | doxazosin | dribbling/terminal dribbling | Dysuria | epididymis | finasteride (Proscar) | frequency | gynaecomastia | haematuria | haematospermia | hesitancy | hydronephrosis | impotence | incontinence | indinavir |Incomplete voiding/emptying | intermittency | isoenzyme | itraconozole | ketoconazole | libido | malaise | mutagen | nefazodon | neoadjuvant therapy | nocturia | oestrogens | phenytoin | phytotherapy | prostate-specific antigen (PSA) | prostatectomy | Qmax | retrograde ejaculation | ritonavir | semen | seminal vesicles | spermatogenesis | tamsulosin | terazosin | testosterone | urgency | urosepsis | verapamil | volume of distribution | warfarin | watchful waiting | weak urinary stream
What’s in this Cholesterol Knowledge Centre?
Cholesterol | LDL/HDL | Lipoprotein Metabolism Cycles | Dyslipidaemia | Atherosclerosis | CV Risk Factors | Clinical Manifestation of Atherosclerosis | Atherosclerosis | Atherogenesis | Prevalence and Incidence | Pathogenesis of Atherosclerotic Plaques | Plaque Formation | Invasive Imaging Techniques Used to Assess Atherosclerosis | Non-invasive techniques | Risk Assessment | Management Guidelines | NCEP ATP III Management Guidelines | Millimol Converter | BMI Calculator | Treatment: Rosuvastatin | Efficacy | Safety and Tolerability | Controlled Clinical trials | Post-marketing surveillance | Pharmacoepidemiology | Fibrates | Bile Acid Sequestrants | Nicotinic Acid (Niacin) | Diet and Exercise | E-Learning | Useful Links | Case Studies | Angina | Arrhythmia | Arteries | Atheromatous Plaque | Atherosclerosis | Bile acids | Cardiovascular Disease (CVD) | Cardiovascular risk factor | Cerebrovascular accident | Cerebrovascular Disease (CBVD) | Cholesterol | Coronary heart disease (CHD) | Dyslipidaemia | Endogenous Pathway | Enzyme | Exogenous Pathway | Fibrates | Framingham Study | Global (or total) cardiovascular risk assessment | Gold standard therapy | HDL - cholesterol A | Intermittent claudication | Ischaemia | LDL-cholesterol | LDL-cholesterol | Lipoproteins | Modifiable risk factor | Myocardial Infarction (MI) | Myocardium | Nicotinic acid | Non-modifiable risk factor | Outcome | Peripheral Vascular Disease (PVD) | Placebo-control | Plaque | Primary Prevention | Randomised | Resins | Risk factor | Secondary prevention | Secretion | Synthesis | Starting dose | Statins Drugs | Titrate | Toxins | Transient ischaemic attack (TIA) | Triglyceride
What’s in this Diabetes Knowledge Centre?
Screening & Diagnosis | Lifestyle management | Oral Agents | Insulin Therapy | Dual Action | Short Term Action | Product benefits | References | Suitable Devices | In pump therapy | The Need For Insulin Analogues | Rationale | IDF 2005 |
What’s in this HPV & Cervical Cancer Knowledge Centre?
Overview | Human papillomavirus (HPV) | Natural History of HPV | HPV Transmission and Acquisition | Cervical Cancer Risk Factors | From Oncogenic HPV to Cervical Cancer | Immunology of HPV Infection | Virology | The Character of HPV | HPV and Cervical cancer | Other Disease Caused by HPV | Epidemiology | Geography | Cervical Cancer and Age | Lifetime Risk of Cervical Cancer | The Cervix | Anatomy | Cell Biology | Immunology of the Cervix | Impact of abnormal screening results, pre-cancerous lesions and cervical cancer | Impact of abnormal screening results, pre-cancerous lesions and cervical cancer on quality of life (QoL) | Impact of Cervical Cancer on Years of Life Lost (YLL) | Societal costs of pre-cancerous lesions and Cervical Cancer | Prevention & Treatment of oncogenic HPV and cervical cancer | Screening for Cervical Cancer | Impact of Abnormal Screening Results | Treatment of CIN and Cervical Cancer | Prevention of Cervical Cancer where screening not implemented | Frequently Asked Questions | References | Acetowhitening | Adenocarcinoma | Age-standardised | Antibody | Antigen / Antigenic | Base pairs | Biopsy | Brachytherapy | Capsid | Cell-mediated | Cervical screening | Chemotherapy | CIN | | CIS | Colposcope | Co-morbid |Cryotherapy | Cytokines | Cytotoxic | Dysplasia / dysplasias | Dysplastic | Envelope | Epidemiology / epidemiological | Epithelial cells/epithelium | False negative | G1 phase | Genome | Homology | HPV | HSIL | Humoral | Hysterectomy | IgG (antibody) | Incidence/incidences | Lesions A general term to describe an area of abnormal tissue | Liquid-based cytology | LSIL | Limphangiogram | Menopause | Metaplastic/metaplasia | Metastasized | Mortality | Neoplastic | Odds ratio | Oncogenesis | Oncogenic |Oncogenic transformation | Pap | Parity | Persistent | Phylogenetics | Primary prevention | Promoter | Radiotherapy / Ionising radiation | Stages | Transcription | Transient | Transformation zone | Triage | Tumour | Vaccination | Vascularisation | Viraemia | Virion | X-rays | Years of life lost (YLL)
What’s in this Hypertension Knowledge Centre?
Home | Definition/Classification hypertension | Diagnostic Evaluation | Cardiovascular Disease Risk Factors | The importance of Systolic Hypertension | Hypertension and the Metabolic Syndrome | Initiating Treatment | Lifestyle Interventions | Pharmacological Interventions | Role played by angiotensin II and the sympathetic nervous system in determining systolic blood pressure | Role played by angiotensin II | Primary intervention studies using AIIAs | A Dual Mechanism of Action | Overview of efficacy with eprosartan in essential hypertension | Eprosartan - effect on systolic blood pressure and pulse pressure | Other Efficacy Trials | Eprosartan in the secondary prevention of stroke: the MOSES study | Effect of eprosartan on blood platelets and fibrinolytic function | Renoprotection: the role of eprosartan | Tolerability and safety of eprosartan | Chemistry and pharmacokinetics of eprosartan | Dosage and administration of eprosartan | Summary: Benefits of eprosartan for patients with high blood pressure | References for Eprosartan | References for Moxonidine | Overview of moxonidine | Monotherapy - Efficacy of moxonidine versus active comparators | Dose-response of moxonidine | Long-term efficacy | Role of moxonidine in combination with other antihypertensives | Moxonidine in postmenopausal hypertensive women | Moxonidine in hypertensive patients with left ventricular hypertrophy | Renal protection: the role of moxonidine | Tolerability and safety of moxonidine | Chemistry and mode of action of moxonidine | The Effects of Moxonidine | Pharmacokinetics of moxonidine | Dosage and administration of moxonidine | Therapeutic Approach in Special Conditions | Resources
What’s in this Insomnia Knowledge Centre?
Home | Insomnia | Types | Characterisation | Classification | Diagnosis | Prevalence | Impact of Insomnia | Understanding Sleep | Monitoring Sleep | Sleep Architecture | Sleep cycle stages | Function of Sleep | Neurobiology of Sleep | Melatonin | Treatment Options | Non- pharmacological | Sleep Hygiene Education | Cognitive Therapy | Alternative Therapies | Melatonin receptor agonists | Circadin | Assessment Tools | Benzodiazepine receptor agonists | Antidepressants | Non prescription medications | Resources | Downloads for Patients | Useful Weblinks | FAQ | Abbreviations | Journal Abstracts
What’s in this Lysosomal storage disorders (LSDs) Knowledge Centre?
About Lysosomal Storage Disorders | When to suspect | Alerting symptoms | Mucopolysaccharidosis Type I (MPS I) | Gaucher disease | Fabry disease | Pompe disease | Diagnosis | Diagnostic tests for lysosomal storage disorders | Treatment options for MPS I, Gaucher, Fabry and Pompe disease | Learn more about lysosomal storage disorders: Disease Information | Learn more about lysosomal storage disorders: Treatment Information | List of relevant literature
What’s in this Men's Health Knowledge Centre?
Home | Hypogonadism | Epidemiology | Etiology | Physiology and Pathophysiology | Biologic Effects of Androgens | Rationale for Therapy | Late-onset Hypogonadism (LOH) | Symptoms | Diagnosis of hypogonadism | Therapy Options | Initiating Treatment | Monitoring | Safety and Tolerability | Clinical Trials/Studies | Reviews | Algorithm | Patient Questionanaire and Evaluation Sheet
What’s in this Meningitis Knowledge Centre?
Home | Types/Causes | Bacterial meningitis | Neonatal meningitis | Viral meningitis | Other causes of meningitis | Transmission | Incidence | Meningococcal Meningitis | Pneumococcal Meningitis | Hib Meningitis | Risk Factors | Symptoms | Impact | Identification | Diagnosing | Diagnosis of Bacterial Meningitis | Neuro-imaging Studies | Diagnosis of Viral Meningitis | Clinical Features | Treatment | Antibiotic Treatment | Anti-inflammatory Agents | Reduction of Intracranial Pressure | Surgery | Chemoprophylaxis | Anti-viral Therapy | Non-pharmacological | Referral | Monitoring | Vaccination | Bacterial meningitis | N. Meningitis | S. Pneumoniae | Viral | Current vaccination policies in European countries | Chemoprophylaxis | Risk Reduction | Web Links | FAQ's | AIDS | Amoeba | Antibiotic | Antigen | Bacterium | Basilar skull fracture | Capsular polysaccharide | Carrier | Cerebrospinal fluid (CSF) | Chemoprophylaxis | Conjugate vaccine | Encephalitis | Endemic | Epidemic | Epidemiology | Fontanelle | Fungus | Gram stain | Haemorrhagic rash | Hib disease | Hib meningitis | Hib vaccine | Hypoglycorrhachia | Immunocompromised | Immunodeficient | Immunogenicity | Immunosuppressed | Meningitis C (MenC) vaccine | Meningitis C conjugate (MenCC) vaccine | Meninges | Meningitis | Meningitis belt | Meningococcal disease | Meningococcal meningitis | Meningococcus | Nasopharynx | Neisseria meningitidis | Neonate | Pleocytosis | Pneumococcal conjugate vaccine (PCV) | Pneumococcal disease | Pneumococcal meningitis | Pneumococcus | Polysaccharide vaccine | Septicaemia | Sequela | Serogroup | Sterile | Subarachnoid space | Tinnitus | Virus
What’s in this Migraine Knowledge Centre?
Home | Is it Migraine? | Migraine: Quick Check | Migraine without aura: International Headache Society classification | Migraine with typical aura: International Headache Society classification | Headache | Primary headache | Secondary headache | Migraine Aetiology | What is Migraine? | What Causes Migraine? | Migraine triggers | Migraine Epidemiology | Economic Impact of Migraine | Treating Migraine | Screening | Diagnosis | Migraine Treatment Guidelines | Headache Care for Practising Physicians (HCPC) | US Headache Consortium Guidelines | Migraine Treatment Options | Acute Migraine Treatments | Triptans | Other acute migraine treatments | Preventative Migraine Treatments | Non-Pharmacological Migraine Treatments | Migraine Treatment Strategies | Step Care Across Attacks | Step Care Within Attacks | Stratified Care | Zomig | Zomig Nasal Spray | 'Zomig Rapimelt' | 'Zomig' Classic Tablets | Zomig full prescribing information | Migraine Disability Assessment (MIDAS) Questionnaire | Patient Diary | Managing Your Migraine Booklet | Migraine & Headache Resources | American Headache Society (AHS) | Analgesics | Migraine Aura | Basilar-type migraine | Biofeedback | Chronic migraine | Chronic paroxysmal hemicrania | Classic migraine (migraine with typical aura) | Cluster headache | Cognitive behavioural therapy | Common migraine (migraine without aura) | Disability In Strategies of Care (DISC) study | Ergotamine | Familial hemiplegic migraine | Headache Care for Practising Physicians (HCPC) | Headache diary | International Headache Society (IHS) | Landmark study | Medication-overuse headache | Menstrual migraine | Migraine Disability Assessment (MIDAS) questionnaire | Migraineur | New daily persistent headache (NDPH) | ODT | Osmophobia | Phonophobia | Photophobia | Primary headache | Prophylactic medication | Secondary headache | Serotonin | Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) | Sinister headache | Tension-type headache |Transcutaneous electrical nerve stimulation (TENS) | Trigger | Triptans | US Headache Consortium |
What’s in this Non-small Cell Lung Cancer Knowledge Centre?
Home | Non-small Cell Lung Cancer | Causes | Risk Factors | Histology/Pathology | Disease Staging/Prognosis | TNM Systems | Factors that affect prognosis | Signs and Symptoms | Diagnosis | Early Stage disease (stage I, II, IIIA) | Treatment Strategies | Advanced disease (stage IV) | Quality of Life in advanced NSCLC | Future Strategies | Treatment Therapies | Chemotherapy | First-line Therapy | Second-line Therapy | Unmet clinical need in advanced NSCLC | Targeted therapies - Overview of cytotoxic drugs | Recent developments in Cancer Cell Biology | Current therapy - Erlotinib | Resources | Downloads - Physicians Materials | Patient | Downloads - Patient support|
What’s in this Ophthalmics Knowledge Centre?
Age-Related Macular Degeneration | Choroidal neovascularization | Clinical development | Efficacy | Safety | Pharmacokinetics | Pharmacodynamics | Administration and light application | Patient information | References | Chronic Eye Discomfort | Allergic Irritation | Allergen Challenge Studies Versus Placebo | Studies with Active Controls | Nasal Effects/Adjuntive or Combined Therapy | Quality of Life | Safety | Product Summary | Delaying Progression | Lutein |The Age-Related Eye Disease Study (AREDS) | Clinical Reports | Physician downloads | Patient Resources
What’s in this Opioids and Pain Knowledge Centre?
Prevalence of chronic pain | Types of chronic pain | Pain measurement | Effects | Initiating opioid therapy | Monitoring | Medication Additional and complementary therapy | Opioids | History | Classification | Why opioids? | Administration | Use in palliative care | Adverse effects | Misconceptions | Web links | Downloads | Multimedia
What’s in this Parkinson's Knowledge Centre?
Pathophysiology of Parkinson's disease | Epidemiology of Parkinson's disease | Making a diagnosis of Parkinson's disease | Guidelines for diagnosing Parkinson's disease | Assessing Parkinson's disease severity | References Cited | Treatment options | Conventional levodopa | Limitations with conventional levodopa therapy | Modification strategies for conventional levodopa | Dopamine agonists | Amantadine | Catechol-O-methyltransferase inhibitors | Monoamine oxidase B inhibitors | Mode of action of anti-parkinsonian therapy | Surgical options | Making therapy choices (based on EFNS guidelines) | Established/advanced Parkinson's disease | Patient communication aids - resources for physicians to provide to patients | LEAP download section | Information for healthcare professionals | Building a Parkinson's disease patient-care team | Diagnostic and patient assessment tools | Publications | Meetings reports | Congress Calendar | Links to international professional groups/organisations
What’s in this Renal Anaemia Knowledge Centre?
Renal Anaemia Home | Definition | Epidemiology of CKD | Incidence and Prevalence of Stage 5 CKD | Treatment of CKD | Renal Anaemia: Definition | Causes | Effects | Challenges | Associated Symptoms | CKD and Anaemia | CKD and renal Anaemia | Implications of CKD related anaemia | AnaemiaWorld | Diagnosis: Overview | Haemoglobin levels in renal anaemia | Diagnostic flow chart | Diagnostic tests: Establishing the cause of anaemia | Diagnostic tests: Determining kidney function | Diagnostic tests: Comorbidities tests | Introduction | Anaemia Treatment In CKD Patients | Current Challenges in the Management of CKD-Related Anaemia | Introducing C.E.R.A | mode of action | Safety | SPC | Clinical Study highlights | Treatment guidelines | Current issues in anaemia management | Useful External Links | Affinity | Anaemia | Biosimilar | Bone marrow | Chronic hypoxaemic pulmonary disease | Chronic kidney disease | CKD-related anaemia | Complete blood count | Correction therapy | Creatinine | Dialysis | Disordered growth signals | End-stage renal disease (ESRD) | Epoetin | Erythrocyte | Erythropoietin | Ferritin | Folate | Glomerulonephritis | Haemoglobin | Homeostasis | Hypertension | Inhibitory concentration (IC50) | Kidney failure | Left ventricular hypertrophy (LVH) | Maintenance therapy | Nephron | PRCA | Pathological organ function | Platelet | Pure red cell aplasia (PRCA) | Red blood cell (erythrocyte) | Renal anaemia Anaemia | Reticulocyte count | Titration period | Transferrin | Vitamin B12